Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Maggiolo

Showing results (91-100 of 150) with videos related to

Pageof 15
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week resultsRichard Elion, Jean-Michel Molina, José Ramón Arribas López, et al.
International Journal of Antimicrobial Agents|July 22, 2021
Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapyRoberta Gagliardini, Nicola Gianotti, Franco Maggiolo, et al.
The New England Journal of Medicine|November 8, 2013
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infectionSharon L Walmsley, Antonio Antela, Nathan Clumeck, et al.
Journal of the International AIDS Society|November 15, 2014
Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohortCarmela Pinnetti, Simona Di Giambenedetto, Franco Maggiolo, et al.
Antiviral Therapy|October 12, 2007
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3Giuseppe Lapadula, Carlo Torti, Franco Maggiolo, et al.
The Journal of Antimicrobial Chemotherapy|August 24, 2012
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohortAntonio Di Biagio, Roberta Prinapori, Diana Giannarelli, et al.
HIV Clinical Trials|July 11, 2007
Predictors of AIDS-defining events among advanced naïve patients after HAARTCarlo Torti, Giuseppe Lapadula, Franco Maggiolo, et al.
The Open AIDS Journal|August 27, 2016
Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal FunctionMaria Concetta Postorino, Eugenia Quiros-Roldan, Franco Maggiolo, et al.
The Journal of Infectious Diseases|August 2, 2014
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patientsMiriam Lichtner, Paola Cicconi, Serena Vita, et al.
AIDS Research and Therapy|June 19, 2012
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class receivedDavide Motta, Nigritella Brianese, Emanuele Focà, et al.
Pageof 15

Showing results (91-100 of 150) with videos related to

Sort By:
Pageof 15
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week resultsRichard Elion, Jean-Michel Molina, José Ramón Arribas López, et al.
International Journal of Antimicrobial Agents|July 22, 2021
Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapyRoberta Gagliardini, Nicola Gianotti, Franco Maggiolo, et al.
The New England Journal of Medicine|November 8, 2013
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infectionSharon L Walmsley, Antonio Antela, Nathan Clumeck, et al.
Journal of the International AIDS Society|November 15, 2014
Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohortCarmela Pinnetti, Simona Di Giambenedetto, Franco Maggiolo, et al.
Antiviral Therapy|October 12, 2007
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3Giuseppe Lapadula, Carlo Torti, Franco Maggiolo, et al.
The Journal of Antimicrobial Chemotherapy|August 24, 2012
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohortAntonio Di Biagio, Roberta Prinapori, Diana Giannarelli, et al.
HIV Clinical Trials|July 11, 2007
Predictors of AIDS-defining events among advanced naïve patients after HAARTCarlo Torti, Giuseppe Lapadula, Franco Maggiolo, et al.
The Open AIDS Journal|August 27, 2016
Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal FunctionMaria Concetta Postorino, Eugenia Quiros-Roldan, Franco Maggiolo, et al.
The Journal of Infectious Diseases|August 2, 2014
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patientsMiriam Lichtner, Paola Cicconi, Serena Vita, et al.
AIDS Research and Therapy|June 19, 2012
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class receivedDavide Motta, Nigritella Brianese, Emanuele Focà, et al.
Pageof 15